BDBM494924 US10994015, Example 15

SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOc2ccc(cc2)-c2cc3c(NCc4ccccc4Cl)ncnc3[nH]2)C(C)(C)C)cc1

InChI Key InChIKey=DJDIVDUVTYANJI-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 494924   

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 690nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 4.70E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 200nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 1.70E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50: 1.90E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
Go to US Patent